Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice.
Elife
; 52016 08 23.
Article
em En
| MEDLINE
| ID: mdl-27549339
ABSTRACT
The FDA approved drug rapamycin increases lifespan in rodents and delays age-related dysfunction in rodents and humans. Nevertheless, important questions remain regarding the optimal dose, duration, and mechanisms of action in the context of healthy aging. Here we show that 3 months of rapamycin treatment is sufficient to increase life expectancy by up to 60% and improve measures of healthspan in middle-aged mice. This transient treatment is also associated with a remodeling of the microbiome, including dramatically increased prevalence of segmented filamentous bacteria in the small intestine. We also define a dose in female mice that does not extend lifespan, but is associated with a striking shift in cancer prevalence toward aggressive hematopoietic cancers and away from non-hematopoietic malignancies. These data suggest that a short-term rapamycin treatment late in life has persistent effects that can robustly delay aging, influence cancer prevalence, and modulate the microbiome.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sirolimo
/
Microbioma Gastrointestinal
/
Longevidade
/
Antibacterianos
/
Antibióticos Antineoplásicos
/
Neoplasias
Tipo de estudo:
Risk_factors_studies
Limite:
Animals
Idioma:
En
Revista:
Elife
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Estados Unidos